Next-generation models and genetic therapies for rare neuromuscular diseases
The MAGIC project is an ambitious four-year (2023-2027) initiative jointly funded by Horizon Europe and UK Research and Innovation (UKRI) bringing together 15 international partners to transform the treatment landscape for muscular dystrophies.
The primary goal of the consortium is to create accurate humanised models of skeletal muscle diseases to enable the precise development of advanced gene therapies and genome editing strategies.
Led by Prof. Francesco Saverio Tedesco from University College London and The Francis Crick Institute, along with the support of Prof. Mario Amendola from Inserm and the Genethon Institute, the MAGIC consortium consists of partners from 9 countries, including academic institutions and research hospitals, small and medium-sized enterprises (SMEs), and charitable organisations:
- University College London, UK (F. S. Tedesco, F. Muntoni, L. Biasco)
- Inserm, France (M. Amendola, G. Ronzitti, D. Gross)
- Hannover Medical School, Germany (H. Buening)
- Université Paris-Est Créteil Val de Marne (F. Relaix)
- Cincinnati Children’s Hospital Medical Center, USA (D. Millay)
- The Francis Crick Institute, UK (S. Rodrigues, F. S. Tedesco, A. Serio)
- King’s College London, UK (P. Zammit, A. Serio)
- Maynooth University, Ireland (K. English, B. Mahon)
- BI/OND Solutions, Netherlands
- VIVEbiotech, Spain
- ReiThera, Italy
- Siegfried DiNAMIQS, Switzerland
- Muscular Dystrophy UK
- Parent Project aps, Italy
- Duchenne Data Foundation, Netherlands
More news and full website coming up soon!
|Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union and HADEA. Neither the European Union nor the granting authority can be held responsible for them.|
|This work is funded by UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee grant numbers 10080927, 10079726, 10082354 and 10078461.|